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Drug delivery to the gastrointestinal (GI) tract is highly challenging due to the harsh environments 
any drug- delivery vehicle must experience before it releases it’s drug payload. Effective targeted drug 
delivery systems often rely on external stimuli to effect release, therefore knowing the exact location of 
the capsule and when to apply an external stimulus is paramount. We present a drug delivery system for 
the GI tract based on coating standard gelatin drug capsules with a model eicosane- superparamagnetic 
iron oxide nanoparticle composite coating, which is activated using magnetic hyperthermia as an on-
demand release mechanism to heat and melt the coating. We also show that the capsules can be readily 
detected via rapid X-ray computed tomography (CT) and magnetic resonance imaging (MRI), vital for 
progressing such a system towards clinical applications. This also offers the opportunity to image the 
dispersion of the drug payload post release. These imaging techniques also influenced capsule content 
and design and the delivered dosage form. The ability to easily change design demonstrates the 
versatility of this system, a vital advantage for modern, patient-specific medicine.
Specific drug delivery for the gastrointestinal (GI) tract is challenging due to the variety of harsh chemical, 
physical, enzymatic and mechanical conditions any delivery vehicle has to endure1–5. This is especially true for 
orally-administered devices, which must endure peristaltic action of the oesophagus, acidic and mechanical abra-
sion of the stomach and alkaline, enzymatic and emulsifying conditions in the intestinal tract before payload 
release. However, oral administration is desirable over intravenous delivery or direct injection into the GI tract 
due to the easy ingestion and minimally-invasive nature of the process, which benefits patient experience.
Traditional orally-administered drug delivery vehicles rely on changes in internal environment in vivo to effect 
release such as changes in pH or enzymatic conditions6–9 or via timed release10–12. Often, the use of internal stim-
uli can lead to unspecific and staggered drug release due to patient-specific differences in GI tract environment, 
which has proliferated the development of externally triggered systems for modern precision medicine13.
The use of an external stimulus to effect drug release is desirable since a physician can control exactly where 
and when a drug payload is released. This approach has been widely explored, using stimuli such as X-rays14, 
ultrasound15–18, light19–21 and by way of magnetic hyperthermia22–26. For the GI tract, the use of magnetic hyper-
thermia has significant advantages over other methods of targeted drug release, particularly the use of radiofre-
quency electromagnetic radiation as the external stimulus which has minimal risk of subsequent complications 
or harmful side-effects27–31. The MACH hyperthermia coil used in this study was itself hand held and cooled 
internally with water in order to prevent any surface tissue damage.
We have found in our previous work that the heat generated from the stimulation of superparamagnetic iron 
oxide nanoparticles (SPIONs) embedded in an hydrocarbon waxy matrix by radiofrequency was sufficient to 
melt the matrix in air and water rapidly22,23. A gelatin drug capsule, loaded with a desired drug payload, was then 
coated in the nanoparticle-wax composite, forming the drug delivery vehicle (Fig. 1). The observed rapid release 
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on application of an alternating radiofrequency field is highly desirable as the drug payload is released directly to 
the site of action, without the need of further, molecular or protein-aided targeting.
The disadvantage of using an external stimulus is the need to determine the location of the drug delivery 
vehicle so that the release stimulus can be provided at the correct time and place to initiate the required release. 
A suitable detection method would need to be rapid, since if the targeted area is missed, the targeted delivery 
has failed in that treatment cycle (although in this case it would still have the advantage that the drug would 
not have been released at all, compared with timed or intrinsic systems where late release would provide a 
therapeutically-ineffective dose to the patient). It would also be able to determine definitively the position of the 
vehicle and ideally also confirm if the vehicle had released it’s payload after the stimulus was applied. The prem-
ise of our proposed drug delivery system is based on the use of cheap, readily available and pharmaceutically- 
approved reagents22,23. Therefore the use of an inexpensive, reliable and easily-applicable detection method would 
be ideal; especially if it is already used routinely in hospital examinations and would require minimal manipula-
tion of the drug delivery vehicle or payload.
To that end, herein we describe solutions to the problem of detection of the capsule and therefore determina-
tion of the release time and location using simulated soft tissue phantoms together with X-ray computed tomog-
raphy (CT) and magnetic resonance imaging (MRI). MRI provides high resolution, non-invasive anatomical 
images, as well as sensitive detection of iron oxides – suiting their use together for various biomedical applica-
tions32,33. Due to the high electron density of iron oxides compared to soft tissue, their inclusion in the capsule 
coating also provides a detection mechanism for CT, which is typically a faster and more cost-efficient imaging 
technique than MRI.
We then go on to demonstrate how inert, clinically-approved contrast agents such as BaSO4 and Iohexol 
could be included within a capsule payload to enable visualisation of its release. By using CT contrast agents with 
physical properties that approximate the drug of interest, we suggest that their dispersal and trafficking in the gut 
could be followed after hyperthermia-mediated release. Finally, we demonstrate the versatility of the above cap-
sule construction and imaging techniques in the production and detection of an alternative drug delivery vehicle 
design that was constructed without the use of a gelatin capsule template.
Experimental
Materials. Barium sulphate (98%), eicosane (99%), octacosane (99%) were purchased from Acros Organics. 
Oleic acid (technical grade, 90%), calcium carbonate (99%), agar (powder, for microbiology), iron (II, III) oxide 
(nanopowder, 50–100 nm particle size (SEM), 97% trace metals basis, used as a magnetite XRD standard) and 
Crystal Violet (hexamethylpararosaniline chloride, > 90%) were purchased from Sigma-Aldrich. Iron(III) chlo-
ride hexahydrate (98%) was purchased from Alfa Aesar reagents. Iron(II) sulphate heptahydrate (98%), sodium 
hydroxide pellets (Analytical reagent grade) and ammonium hydroxide solution (28% in water) were purchased 
from Fisher Scientific, and perfluorooctyl bromide (PFOB, 97%) from Fluorochem Ltd. Iohexol (Omnipaque 
300) was obtained from GE healthcare. Aspirin tablets were bought commercially from Boots Ltd. Laboratory sol-
vents were purchased from Sigma Aldrich Limited and were of analytical grade. Aqueous solutions were prepared 
Figure 1. Process of capsule synthesis and mechanism of drug release. (a) demonstrates a SPION-wax 
coated drug capsule which, when at the desired point of release, is then irradiated with radiofrequency, heating 
the SPIONs and melting the wax coating, (b). Water ingress then dissolves the gelatin drug capsule template, 
(c) before release of the drug payload, (d). In order to prevent wax melting during incorporation into an agar 
phantom for MRI/CT imaging, a thin layer of pure octacosane (m.p. 57–62 °C) was added via dip-coating,  
(e). The octacosane-SPION-wax coated capsule was then incorporated into an agar phantom at ~40 °C, (f).
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using UHQ deionised water with a resistivity of not less than 18.2 MΩ cm−1. N2 (oxygen free) gas was purchased 
from BOC Ltd. and used as received. Gelatin capsules were purchased from CapsulCN, China.
Methods
Synthesis of iron oxide nanoparticles. Iron oxide nanoparticles were synthesised using a co-precipita-
tion method based on the protocol outlined by Lopez-Lopez et al.34. Briefly, iron(II) sulphate heptahydrate (8.97 g, 
32.3 mmol) and iron(III) chloride hexahydrate (17.08 g, 61.3 mmol) were dissolved in 90 and 100 ml degassed 
deionised water respectively. These solutions were combined under vigorous stirring and the pH increased to 10 
using 30% v/v ammonia solution (diluted from conc., 28% in water), resulting in the formation of the Fe3O4 nan-
oparticles. Oleic acid (8 ml, 2.53 mmol) was added, and the solution continued to be vigorously stirred for 1 hour. 
The suspension was then heated to 95 °C at a constant rate of 2 °C min−1, and left to cool to room temperature as 
soon as 95 °C was reached. The pH was then decreased to 5 using sulphuric acid (45%, 8.5 ml) and left to coagulate 
(ca. 30 min). After removal of liquid, the resulting black solid was washed four times with water and then once 
with acetone, before drying in vacuo.
Capsule coating. Capsules were coated with a molten eicosane/SPION mixture according to our previous 
work with modifications22,23. Briefly, the eicosane/SPION layer was applied to the capsules via a paint brush using 
an homogenised molten SPION (at a chosen concentration) in eicosane (ca. 50 °C) dispersion. A complete coat-
ing was achieved by waiting for the molten layer to cool before applying another coat. The process was repeated 
for the addition of subsequent layers up to a total of 3 layers (1.5 mm thickness). It was found that a 13:7 (wt:wt) 
SPION:eicosane ratio was the optimal, as the eicosane/SPION mixture could still be easily handled, melted and 
used as a coating, yet had a high SPION content.
Hyperthermia release. Capsule content release was effected by magnetic hyperthermia in air, or whilst 
suspended in agar or water phantoms (vide infra).
Imaging in agar and water phantom media. Agar phantoms were prepared from 2% w/v agar dis-
solved by heating to boiling (~100 °C) in distilled water, and set into 50 mL Falcon tubes. Capsules were manually 
embedded in the agar just before the setting temperature was reached.
Before coating, capsules were loaded with an arbitrary amount (ca. 0.1 g) of a contrast agent (barium sulphate, 
perfluorooctyl bromide or lyophilized Iohexol). Capsules required an extra coating of octacosane (m.p. 57–62 °C) 
to prevent melting of the coating under the high temperature (40 °C) of the agar phantom before setting. This was 
not required for samples in water phantoms.
Instrumentation. Transmission electron microscopy (TEM) images were obtained using a high resolution 
TEM Jeol 2100 with a LaB6 source operating at an acceleration voltage of 200 kV. Images were recorded on a Gatan 
Orius Charge-coupled device (CCD). Samples were drop-cast onto carbon-coated 400 mesh copper grids (Agar 
Scientific Limited, UK). Dynamic Light Scattering (DLS) was measured using a Malvern Zetasizer Nano-ZS. 
Powder X-ray diffraction (pXRD) patterns were recorded using a Stoe (Mo) StadiP diffractometer with a Mo 
X-ray source (Mo tube 50 kV 30 mA, λ = 0.70926 Å), monochromated (Pre-sample Ge (111) monochromator 
selects Kα 1 only) and a Dectris Mython 1 k silicon strip detector covering 18° 2θ . Magnetisation data was taken 
using a Quantum Design MPMS Super conducting Quantum Interference Device (SQUID) VSM Magnetometer 
(San Diego, USA) at 300 K using a field range of ± 7 T. Hyperthermia experiments were undertaken using a 
MACH system (Magnetic Alternating Current Hyperthermia) designed and built by Resonant Circuits Limited 
(3.52 kA/m and the frequency is 990 kHz)35. The temperature was monitored using a fluoroptic [fibreoptic] 
temperature probe (Luxtron FOT Lab Kit, Lumasense California USA). Thermal images were recorded with an 
Infratec (Germany) VarioCAM HR research 780 with 30 mK thermal resolution and 1280 × 960 spatial resolu-
tion. Capsules were mounted in a weighing boat in air, or loaded with sand (to increase their density) for sub-
merged experiments. X-Ray photoelectron spectroscopy (XPS) was performed using a Thermo Scientific K-alpha 
spectrometer with monochromated Al Kα radiation, a dual beam charge compensation system and constant pass 
energy of 50 eV (spot size 400 μ m). Survey scans were collected in the range 0–1200 eV. High-resolution peaks 
were used for the principal peaks of Fe (2p), O (1 s) and C (1 s). Magnetic Resonance Images were obtained using 
a 1T Brüker ICON desktop MRI system (Brüker BioSciences Corporation, Ettlingen, Germany), interfaced to an 
operating console running Paravision 5 software (Bruker). A 44 mm rat body solenoid RF coil (Brüker) was oper-
ated on transmit/receive mode. Multi-slice images were acquired using a spoiled gradient echo sequence with TE 
of 6.2 ms and a TR of 387 ms, 2 averages, and an 80° flip angle. Images were acquired for a 4 × 4 cm field of view 
with 256 × 256 in plane resolution, and 20 slices of 2 mm thickness with 2.25 mm separation. Total scan time was 
3 minutes 19 seconds per sample. Volume rendering was done using ImageJ software. CT images were obtained 
using a Nanoscan PET/CT (Mediso), with tube voltage of 50 keV, 30 ms exposure, and 720 projections, operated 
using Nucline 2 software (Mediso). Total scan time was 3 minutes 46 seconds per sample. Reconstructions were 
done with Nucline 2 software, analysis and volume rendering was done in Vivoquant (inviCRO) and Interview 
Fusion (Bartec) software.
Results and Discussion
Iron oxide nanoparticles were synthesised using a co-precipitation method, by the precipitation of magnetite 
Fe3O4 from an aqueous solution of ferrous and ferric salts in basic conditions. The precipitate was subsequently 
treated with oleic acid to ensure the particles were readily dispersible in organic media. This ensured even particle 
distribution throughout the wax coating matrix and even, rapid heating throughout. This is important as it mini-
mises patient exposure to the hyperthermia magnetic field, and decreases overall treatment time.
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The co-precipitation method for the synthesis of iron oxide nanoparticles is a scalable method for the rapid 
production of magnetic material. However, products are typically highly polydisperse (Fig. 1a)) when compared 
to hydrophobic ligated magnetic nanoparticles synthesised by thermal decomposition methods36–41. The inher-
ent polydispersity however can be seen as an advantage due to the array of commercially-available and bespoke 
magnetic hyperthermia apparatus, each generating different field strengths and frequencies42. Therefore, a poly-
disperse SPION sample is more likely to be compatible with a wider range of hyperthermia instruments.
TEM analysis of the nanoparticles obtained by co-precipitation demonstrates a polydisperse sample with 
an average size of 8.5 nm and a standard deviation of 3.6 nm. This is supported by the solvodynamic radius of 
15.3 ± 3.61 nm obtained by DLS (Fig. 2d), after washing and re-dispersion in n-hexane. This is a larger value than 
that obtained for the core size by TEM as this includes the oleic acid ligand corona. High resolution TEM analysis 
(Figure S2) gave lattice d-spacings of 0.90 nm and 0.248 nm, which are assigned to the < 220> and < 311> planes 
of magnetite.
The XRD pattern of the nanoparticles was assigned as iron oxide, presumed to be that of magnetite (Fig. 2c), 
ICSD 26410, magnetite Fe3O443. Note that an Fe3O4 control (97%, Sigma Aldrich) was run as a control and that 
the radiation used was Molybdenum Kα (λ = 0.70926 Å).
The magnetic properties of the nanocrystals were analysed by SQUID magnetometry. Saturation magneti-
sation values of 84.7 emu g−1 and 21.7 emu g−1 were recorded for 21.5 mg of SPION sample and 13.1 mg of the 
sample dispersed in eicosane wax (13:7 wt:wt) respectively. The complete absence of magnetic hysteresis and zero 
coercivity in any of the samples and their small size as evidenced by TEM and DLS, indicated that the nanopar-
ticles are superparamagnetic at 300 K. XPS analysis of the SPIONs showed the presence of iron and oxygen (Fe 
2p3/2, binding energy 710.9 eV) and (O1 s, binding energy 530.1 eV) assigned as Fe3O444–47. Further O1 s peaks are 
assigned as FeOOH (binding energy 531.8 eV) and O in organic species (presumed to be oleic acid, COO, binding 
energy 533.4 eV)48.
As-synthesised SPIONs were subsequently dispersed in molten eicosane at 50 °C before application of the 
coating via a paintbrush to the capsule surface. Around 3 complete coatings were necessary to ensure the capsule 
was impervious to water. Capsules were heated in both water and air to demonstrate effective melting of the 
capsule coating. In our previous work, the authors investigated the composition, melting properties and sta-
bility under physiological conditions of various wax-SPION composite coatings22,23. We concluded that a wax 
containing a mixture of eicosane and docosane (40/60 w/w, m.p. 42 °C) would be the best candidate in order to 
melt above body temperature, but not be too high as to damage extraneous tissue. In all wax composites trialled, 
Figure 2. (a) TEM micrograph of 8.5 nm iron oxide nanoparticles showing polydispersity, with an average core 
size of about 8.5 nm, (b) SQUID magnetometry measurement showing a saturation magnetisation of 84.7 emu g−1 
at 300 K and the absence of hysteretic behaviour indicating superparamagnetism, (c) an XRD pattern of iron oxide 
nanoparticles (compared with a magnetite standard below) and (d) an average DLS size (by number, 15.3 ± 3.61 nm).
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the SPIONs exhibited good dispersion in all wax composites, therefore making the melting point of the coating 
tuneable according to the melting point of the wax used. In this study, we utilised eicosane simply as a model 
hydrocarbon wax for imaging purposes, as in vivo tests would require the aforementioned higher melting point 
eicosane-docosane composite.
The materials used to synthesise the capsules and capsule coatings are pharmaceutically approved (i.e. all 
the chemicals used are listed in the British Pharmacopoeia either as medications in their own right (e.g. ferrous 
sulphate B.P. for treatment of anaemia), as components of other medications (e.g. oleic acid in emulsions and 
ointments) or in less refined forms (e.g. eicosane is a component of white soft paraffin/petroleum jelly)).
Temperature versus time data extracted from the thermal imaging camera was used for the capsule in air 
(Fig. 3a). Although an attached fibreoptic thermocouple was used for the heating of the capsule in water in 
(Fig. 3b), the disintegrating nature of the melting coating made this exacting, so where appropriate, the ther-
mal camera was used. As seen previously22,23, the heating curve in air displayed initial heating to a plateau. This 
plateau is due to the energy required to supply the latent heat of melting, hence a plateau was observed as the 
material undergoes phase transition to a liquid. The incorporation of SPIONs tend to lower the melting tempera-
ture of the composite from the literature melting point of eicosane (35–37 °C), although incorporation of higher 
molecular mass alkanes again raises the melting point23. Rapid heating was observed as the solid eicosane matrix 
became liquid.
In (Fig. 3b), heating and melting of the capsule in water was achieved even though the fibreoptic thermo-
couple attached to the coating decoupled from the disintegrating coating and was subsequently cooled by the 
surrounding water (see photographic stills S4.3–4.5).
The ability of a 1 Tesla MRI system to detect the iron oxide-wax-coated capsules was assessed. The presence 
of iron oxides in tissue should produce a hypo-intense signal due to the dephasing of surrounding water pro-
ton spins, proving a potential clinically-applicable means to detect the capsules and their transit in patients. To 
Figure 3. (a) Graph of heating an eicosane- SPION coated capsule in air demonstrating heating behaviour 
commensurate with the latent heat of melting of eicosane and (b) submerged in water. Melting was difficult to 
observe via an attached thermocouple as the thermocouple detached as the material melted, (c,d) are thermal 
images showing progression of melting with time, at 105 seconds in (c) and 285 seconds in (d) for the capsule 
heated in air.
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approximate the surrounding soft tissue contrast in the gut, capsules were embedded in a 50 ml volume of 2% 
agar prior to imaging.
Multi-slice images were taken across the capsule and agar phantom, and reconstructed into 3D volumes, 
Fig. 4. In the capsules coated in wax only, the cavity and coating of the capsule can be seen as a hypo-intense 
region against the background signal provided by the agar (Fig. 4a_c). In the capsules coated in the wax-iron oxide 
composite, however, the hypo-intense region was enlarged, resulting in a drop out of signal from all but the top 
edges of the agar phantom (4d to f). Coatings on only one half of the capsule, or as dots on the capsule, produced 
intermediate volumes of hypo-intensity between those of the capsules with wax only, and a full coating of iron 
oxide-wax (4 h to m). The large amount of iron in the coatings required for hyperthermia-mediated drug release 
precluded the possibility of obtaining accurate T2 maps, due to the extreme T2 shortening.
One potential limitation of iron-based contrast agents for MRI is the “blooming” effect, whereby signal 
hypo-intensity is produced over a greater area than that which contains the contrast agent, Fig. 5. Though this 
Figure 4. Magnetic resonance images showing signal hypointensity produced by iron oxide wax-coated 
capsules compared to capsules coated in the wax only. Axial (a,e,h,k), and coronal slices (b,f,I,l) through the 
capsules are shown, as well as a volume rendering of the agar phantom containing the capsules.
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can increase the sensitivity with which iron oxides can be detected, it can also reduce the accuracy of locating 
the contrast agent, as well as obscuring anatomical features that might be important for reference when targeting 
delivery. A second limitation is the potential inability to distinguish between the presence of T2 contrast agents 
such as iron oxides, and endogenous areas of signal hypo-intensity and susceptibility artefacts caused by gas/
tissue interfaces in the bowel. For these two reasons, we next chose to investigate the incorporation of X-ray CT 
contrast agents into the capsules, which should provide the advantages of both positive contrast and a less ambig-
uous mode of detection. Furthermore, the use of CT is significantly cheaper and quicker than MRI in the clinic, 
providing a better option for translation. CT scanning is sufficiently fast as to give a pinpoint location of the cap-
sule. Gastrointestinal transit time may be increased or decreased with the use of appropriate binding medication 
or laxatives respectively to aid detection49–52. In this way, hyperosmotic agents increase the water content of the 
intestine and so can change the environment in which the delivery occurs. This is advantageous in both detection 
and drug release and diffusion.
We then showed that CT imaging could detect the iron oxide wax coating, which provided signal above that 
of the simulated soft tissue contrast of the agar phantom, Fig. 5. The X-ray absorbance of the iron-oxide wax was 
Figure 5. (a) CT images showing capsules coated in wax only (Eicosane), iron-oxide wax coating, and the iron 
oxide-wax coated capsules filled with BaSO4, Perfluorooctylbromide (PFOB), and Iohexol. (b) Quantification 
of radiopacity of the capsules shown in (a). Bars show mean X-ray absorbance of all pixels contained within 
the capsule coating or filling, error bars show SD of the whole segmented region in the capsule cavity. The 
absorbance of air, water, abdomen soft tissue, and bone are provided for reference.
www.nature.com/scientificreports/
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measured at 952 ± 297 HU, which is above the typical soft tissue absorbance of around 30 ± 5 HU53, and close to 
the strong radiopacity of bone (1000 to 1600 HU). In comparison, the eicosane wax without iron oxide gave much 
lower X-ray absorbance than both the iron oxide wax and soft tissue (− 473.798 ± 183.650 HU), showing that it is 
the addition of the iron oxide to the wax that is responsible for its ability to produce CT contrast54. This suggests 
that X-ray imaging might provide an effective means to track the location and break-up of the iron-oxide wax 
coated capsule without the addition of any further encapsulated contrast agents. However, this would not provide 
information on the release and subsequent diffusion of encapsulated drugs.
To demonstrate the ability to image the triggered release of the capsule contents, three different CT contrast 
agents were encapsulated (Barium sulfate (BaSO4), perfluorooctyl bromide (PFOB), and Iohexol), and the cap-
sules imaged with CT, Fig. 5. Of these, BaSO4 and Iohexol are in routine clinical use55, and the PFOB-based CT 
contrast agent Imagent BP ® has also been approved for clinical use by the FDA56,57. These agents therefore provide 
a safe method for tracking the release of encapsulated contents upon hyperthermia-mediated dissolution of the 
capsule. CT images revealed that further contrast was provided by the inclusion of these encapsulated CT contrast 
agents: BaSO4 (7672.88 ± 2414.30 HU), PFOB (5950.51 ± 1382.75 HU), and Iohexol (7417.74 ± 3437.47 HU). The 
increase in radiopacity provided by these was much greater than that of the iron-oxide wax, and several fold that 
of bone.
Next, water-based phantoms containing the capsules with CT contrast agents were prepared. For the imaging 
to provide representative information on drug release, it is important to have contrast agents that behave in a 
similar way to the encapsulated drug of interest, so that their release from the capsule and absorption or traffick-
ing in the bowel would be similar to that of the drug. For this reason the three CT contrast agents were selected 
to display different physical behaviour- BaSO4 (insoluble, granular), PFOB (liquid, immiscible in water), and 
Iohexol (powdered, soluble in water). In particular, the PFOB and BaSO4 mimic poorly soluble drugs with limited 
bioavailability, and any dissolution steps any such drug might have to overcome, for example if it was encased in 
an amphiphilic polymer58–60. These were imaged before and after release, to assess the ability of CT to visualise 
dispersal of the capsule contents. Figure 6 shows that contents release can be visualised with BaSO4, PFOB, and 
Iohexol filled capsules. In the case of BaSO4 and PFOB, in which the contents are not soluble in water, the released 
contents can be seen lining the base of the tube of water into which they have been released. In the case of Iohexol, 
which is water soluble, it can be seen that the contrast agent has dissolved, confirming that the contents of the 
capsule have been exposed to the exterior aqueous environment after heating.
The preceding capsule designs used in Figs 3_6 have relied on a gelatin capsule template that is filled with the 
drug of interest and contrast agent, prior to coating with the waterproof iron-wax composite. However, to sim-
plify the design of the system, a gelatin capsule-free approach was investigated, in which the drug and contrast 
agent were compacted into a solid tablet, then coated directly in the iron-wax composite. Using this approach, we 
successfully incorporated BaSO4 and Iohexol into a commercial aspirin formulation at 25 and 10% w/w respec-
tively. CT images showed that these tablets also appeared bright on CT images (Fig. 7), again with much higher 
radiopacity than bone.
Post-release, it was observed that the capsule wax coating was entirely removed from the aspirin template on 
exposure to an external magnetic field, once again showing the viability of the on-demand, rapid triggered release 
mechanism. However, due to the largely insoluble nature of the formulation including substances such as calcium 
carbonate and talc, which is a lubricating agent in the tablet manufacturing process, the aspirin formulation also 
proved to only be very sparingly soluble in acidic conditions (~pH 3), with the coating protecting the payload 
(48 hours) without incident until release was effected by hyperthermia. Nevertheless, the incorporation of Iohexol 
Figure 6. CT images show iron-oxide wax coated capsules containing CT contrast agents before and after 
triggered release (60 minutes). Post-release images show the distribution of the released contrast agents.
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and BaSO4 was highly effective in aiding CT imaging in this exemplar system, and with a near limitless number of 
pharmaceutical formulations possible, the iron oxide wax composite coating has a bright future.
Furthermore, this demonstrates the influence of detection on capsule design, and indeed the versatility of 
hyperthermia-activated drug delivery coatings, especially in challenging target organs such as the GI tract. In 
this way, the release of powdered, poorly soluble drugs specifically to locations in the GI tract, locally increasing 
bio-availability can be realised, with a focus on affordable patient-specific dosage-form design.
Conclusion
Hyperthermia-controlled drug release has been demonstrated using an eicosane/SPION composite coated deliv-
ery vehicle. Our robust iron oxide wax capsule coating can provide contrast on both X-ray computed tomography 
(CT), and magnetic resonance imaging, providing a clinically- applicable means to monitor transit of the delivery 
vehicle in order to control release in specific portions of the GI tract. We have also demonstrated the feasibility of 
MRI for detection, however superior cost effectiveness and throughput (seconds to minutes per scan, depending 
on the application)61 make CT imaging more desirable. By encapsulating CT contrast agents into the vehicle 
design, it is possible to image contents release using CT to confirm drug delivery at the target site. It is notewor-
thy that the eicosane/SPION composite itself exhibited CT contrast comparable to that of bone (952 ± 297 HU 
vs. 1000 to 1600 HU for strong radiopacity of bone) without the addition of contrast agents such as BaSO4 and 
Iohexol.
Detection has also influenced capsule design, with iron oxide wax applied so as to create a unique shape for 
MRI, thus readily distinguishing it from air pockets in the gut. Other pharmaceutical formulations, such as the use 
of powdered drugs with contrast agents pressed into a pellet were also examined. This enables the rapid increase 
in local bio-availability of poorly soluble drugs, with a focus on affordable patient-specific capsule design. These 
improvements, along with the intrinsic simplicity of the vehicle and release mechanism and detection strategies 
Figure 7. (a) CT images showing coronal CT slices, a reconstructed maximum intensity projection, and 3D 
volume rendering of the Aspirin tablets coated with the iron wax composite, embedded in 2% agar. Addition of 
Iohexol or BaSO4 improved CT visibility. Post-release images showed the degradation of the coating completely 
and the partial dissolution of the aspirin template. (b) Quantification of radiopacity of aspirin tablet with iron 
wax coating, and aspirin table incorporating 25% w/w BaSO4 or 10% w/w Iohexol. Error bars represent the 
standard deviation in Hounsfield units of all pixels in the 3D region of interest shown segmented in the 3D 
volume render image in (a).
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demonstrate the versatility of our system and will aid future translation to the clinic. The approach outlined in 
this work is generic, so in principle almost any pharmaceutical formulation could be packaged and released in 
this way. It would also be possible to engineer much more sophisticated multi-compartment or multi-component 
devices with additional features to enhance drug release or dissolution or minimise the loading of iron-oxide wax 
coating to reduce the required magnetic field exposure, though it should be emphasised that the fields used in this 
work are well within acceptable limits for clinical application.
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